Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$134K Sell
1,352
-87
-6% -$10.5K 0.01% 1114
2026
Q2
$192K Sell
1,439
-47
-3% -$5.32K 0.01% 948
2026
Q1
$165K Buy
1,486
+11
+0.7% +$1.3K 0.01% 937
2025
Q4
$199K Buy
+1,475
New +$161K 0.01% 869

Other funds holding ABVX

BFC Planning's ABVX Position: Q3 2026 in Review

BFC Planning reduced its Abivax (ABVX) stake by 6% in Q3 2026, selling an estimated $10.5K and leaving 1,352 shares worth $134K. The position accounts for 0.01% of the portfolio, ranked #1114.

BFC Planning first reported a position in ABVX in Q4 2025 and has held it in 4 quarters since. The position peaked at $199K in Q4 2025. 218 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • BFC Planning held 1,352 shares of Abivax worth $134K as of Q3 2026.
  • BFC Planning sold 87 Abivax shares in Q3 2026, an estimated $10.5K.
  • Abivax made up 0.01% of BFC Planning's portfolio in Q3 2026, its #1114 holding.
  • BFC Planning first reported a position in Abivax in Q4 2025 and has held it in 4 quarters since.
  • BFC Planning's Abivax position peaked at $199K in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.